ArticleNPJ vaccines2025
DNA vaccine targeting betacoronavirus spike protein blocks neuroinvasion and neuroinflammation in swine via dual antiviral-immunomodulatory action.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice.Virologica Sinica · 2025Article
- Dysregulated Resolution of Inflammation After Respiratory Viral Infections: Molecular Pathways Linking Neuroinflammation to Post-Viral Neuropathic Pain-A Narrative Review.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Porcine hemagglutinating encephalomyelitis virus (PHEV), a neurotropic betacoronavirus, causes fatal neurological disease in piglets, yet no licensed vaccines exist. Here, we developed a DNA vaccine encoding the receptor-binding domain (RBD) of PHEV spike protein fused to IgG1 Fc, adjuvanted with GEL01 (RBD + GEL01). Immunization in mice and piglets elicited robust neutralizing antibodies (titers up to 1:446 and 1:147, respectively) and Th1-biased cellular immunity. The vaccine restricted viral neuroinvasion, reducing brain viral loads by >90% and confining PHEV to discrete olfactory and cortical regions. Vaccinated animals exhibited preserved motor coordination, cognitive function, and minimal neuropathology. Transcriptomic analysis revealed suppression of proinflammatory mediators (e.g., Cxcl2, Saa3) and enhanced neural repair pathways, highlighting dual virological control and immunomodulatory mechanisms. As the first DNA vaccine against PHEV, the RBD + GEL01 candidate offers scalable protection against neurotropic coronaviruses by dual antiviral-immunomodulatory strategy, underscoring its potential to mitigate economic and zoonotic risks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.